SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending with community chatter focusing on the stock's recent upward momentum, driven by speculation around potential catalysts and technical factors. Some traders point to a possible gamma squeeze and overall market strength, while others express skepticism, citing valuation concerns and mixed fundamentals. The discussion includes debate on whether the rally is sustainable or if a pullback is imminent.

Gemini Space Station Inc. - Ordinary Shares- Class A

Gemini Space Station

Gemini Space Station's IPO is trending amid volatile price action, sparking debates about IPO allocations and the influence of retail investors. The community is weighing the long-term potential against concerns over reported losses and the overall crypto market sentiment, while also comparing it to other recent IPOs. Some traders express excitement about potential gains, while others are wary of the stock's high valuation and the involvement of the Winklevoss twins.

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Atyr Pharma Inc

aTyr Pharma, Inc

Anticipation is building around aTyr Pharma as it approaches the topline Phase 3 data release for efzofitimod in pulmonary sarcoidosis, driving significant community discussion. While some traders are eyeing a potential pump and dump scenario, others are optimistic about the trial's outcome and future indications, highlighting strong institutional ownership and potential for a short squeeze. The community is closely monitoring for any data leaks and debating the influence of prominent figures on the stock's movement.

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is trending as the community discusses potential partnerships and integrations, particularly within the Solana ecosystem. Bullish sentiment is fueled by discussions around real-world asset (RWA) adoption and the anticipation of increased volume as more markets open.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer ($PFE) is trending due to reports suggesting the Trump administration may link COVID-19 vaccines to child deaths, sparking concerns about potential liabilities and renewed scrutiny of vaccine safety data. The community is debating the validity of the reports and the potential impact on vaccine manufacturers, while some investors see the dip as a buying opportunity for the high-dividend stock.  Others believe Pfizer is more than just a vaccine company and should be evaluated as a cancer treatment company.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IONQ is trending due to regulatory clearance for its acquisition of Oxford Ionics, sparking discussions about the company's future and potential catalysts such as the upcoming Quantum World Congress. Community perspectives are mixed, with some highlighting the acquisition's significance while others express concerns about revenue and valuation. The stock is also being compared to NVDA, with some seeing it as the next big thing in computing.

FuelCell Energy, Inc. engages in the business of developing, designing, producing, constructing, and servicing high temperature fuel cells for clean electric power generation. It operates through the following geographical segments: the United States, South Korea, and Europe. The company was founded by Bernard Baker and Martin G. Klein in 1969 and is headquartered in Danbury, CT.

Fuelcell Energy Inc

FCEL is trending due to recent earnings and increased discussion around its potential in AI data center power, with community members highlighting its fast “contract-to-power” deployment. Some are expressing optimism for a continued rally, while others are debating the company's path to profitability and comparing it to sector peers like BE and PLUG. Discussion also includes potential catalysts such as new deals, partnerships, and broader adoption of clean energy initiatives.

Sonnet BioTherapeutics Holdings, Inc. is a clinical stage biotechnology company, which engages in the innovation of biologic medicines. Its Fully Human Albumin Binding (FHAB) technology utilizes a single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its pipeline focuses on cytokines, a class of cell signaling peptides that, among other important functions, serve as potent immunomodulatory agents. The company was founded by Pankaj Mohan and John K. Cini in 2011 and is headquartered in Princeton, NJ.

Sonnet BioTherapeutics Holdings Inc

SONN is trending due to news of a business combination to launch a cryptocurrency treasury reserve strategy, causing a premarket surge and high volatility. The community is discussing the potential for a pump and dump, dilution concerns, and the impact of the deal on long-term value for shareholders. The pivot from biotech to crypto has triggered both excitement and skepticism.

Asset Entities, Inc. engages in providing social media marketing and content delivery services. It offers its services to Discord, TikTok, and other social media platforms. It also designs, develops and manages servers for communities on Discord. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani and Kyle Fairbanks on August 1, 2020 and is headquartered in Dallas, TX.

Asset Entities Inc - Ordinary Shares - Class B

Asset Entities Inc.

Asset Entities Inc. is trending as traders anticipate the closing of its merger with Strive, potentially transforming it into a Bitcoin treasury company; high short interest and borrow fees add to the excitement, with the community debating the impact of potential dilution and the timing of news releases, as well as the possibility of a short squeeze. Despite some volatility, many investors express confidence in the long-term potential, urging others to hold firm.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is trending following news that its Black Widow drone system has been approved for NATO procurement, potentially opening up significant sales opportunities. Community members are actively discussing the implications of this approval, particularly its long-term impact and revenue potential, while also debating the stock's valuation compared to sector peers. Bullish sentiment revolves around the expectation of increased revenues and potential contracts stemming from NATO countries.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Rocket Lab (RKLB) experienced a more than 700% increase in retail user message count on Stocktwits over the last 24 hours as of Wednesday morning, and was the top-trending stock on the platform.Retail sentiment on <a href="https://stocktwits.com/symbol/RKLB">Rocket Lab</a> improved to ‘extremely bullish’ from ‘bullish’ territory a day ago, with message volumes at ‘high’ levels, according to data from Stocktwits.<figure class="image"><img style="aspect-ratio:796/107;" src="https://news.stocktwits-cdn.com/RKLB_sentiment_png_2310e5aede.webp" alt="RKLB sentiment.png" width="796" height="107"><figcaption>RKLB sentiment and message volume September 3, 2025, as of 1:10 pm ET | Source: Stocktwits</figcaption></figure>The stock's watchlist count on Stocktwits doubled to 43,281 in a year.Notably, the company's shares declined 10% by midday trading on Wednesday, despite no stock-specific news. The shares appear to have taken a breather following the massive rally seen over the last year. Rocket Lab shares have gained 75% this year and have jumped over 600% over the previous 12 months.Last week, Roth Capital also raised its price target on Rocket Lab to $60 from $50 and maintained a ‘Buy’ rating, according the TheFly. The firm noted that it was impressed by Rocket Lab's progress toward the initial Neutron launch.The Neutron support infrastructure and launch pad infrastructure are all in place for initial launch, Roth Capital said. Rocket Lab opened Launch Complex 3 on August 28, its dedicated test, launch, and landing facility for its reusable rocket, Neutron. The pad is located within the Virginia Spaceport Authority’s (VSA) Mid-Atlantic Regional Spaceport (MARS) at Pad 0D on Wallops Island, Virginia.The company stated that Launch Complex 3 is poised to deliver the largest orbital launch capacity in the Spaceport’s history with Neutron, which is capable of launching 13,000 kg to space for commercial constellations, national security, and interplanetary missions, as well as eventually supporting human spaceflight.In late August, Rocket Lab&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rklb-stock-lifts-off-10-after-70th-electron-launch/chssMD9RdSc">launched</a> its 70th Electron mission as part of its ‘Live, Laugh, Launch’ mission.&nbsp;The ‘Live, Laugh, Launch’ was Electron’s 12th mission of 2025 as Rocket Lab continues to execute an accelerated schedule of Electron launches.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/campbells-ceo-flags-consumer-caution-sees-surge-in-home-cooking/chwcc2mRdoR">Campbell’s CEO Flags Consumer Caution, Sees Surge In Home Cooking And Wellness Demand</a>

Rocket Lab’s 360% surge so far in 2024 has brought CEO Peter Beck’s 10% stake in the company to $970 million. | Source: Rocket Lab USA 

This Aerospace Stock Witnessed A 700% Explosion In Retail Chatter On Stocktwits – More Details Inside

Last week, Roth Capital raised its price target on Rocket Lab to $60 from $50 and noted that it was impressed by the company’s progress toward the initial Neutron launch.

Equity

Autonomous driving technology company Mobileye Global Inc. (MBLY) on Thursday increased its full-year revenue guidance and lowered its operating loss forecast, citing continued strength in supply-demand dynamics and increased demand for its autonomous driving chips.“Stronger visibility on industry supply-demand alignment since late-April supports our decision to raise the full-year outlook, while we continue to maintain a conservative stance given the broader macro environment,” <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.mobileye.com/news-releases/news-release-details/mobileye-releases-second-quarter-2025-results-updates-full-year">said</a> Mobileye President and CEO Amnon Shashua, while also predicting an “inflection” in the company’s growth trajectory in 2027.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/MBLY">Mobileye</a> jumped from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:623/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_24_at_8_53_36_AM_png_4bc34a33af.webp" alt="MBLY's Sentiment Meter and Message Volume as of 8:53 a.m. ET on July 24, 2025 | Source: Stocktwits" width="623" height="60"><figcaption>MBLY's Sentiment Meter and Message Volume as of 8:53 a.m. ET on July 24, 2025 | Source: Stocktwits</figcaption></figure> The company now expects revenue of $1.77 billion to $1.89 billion for the full year 2025, up from its previous guidance range of $1.69 billion to $1.81 billion.Operating loss is expected to be between $512 million and $436 million for the year, which is narrower than the company’s previous estimate of $574 million to $489 million in operating loss.The company stated that the new guidance includes its estimates of production impacts related to current tariffs imposed on complete vehicles imported into the United States, as well as tariffs on imported vehicle components used in U.S. vehicle production. However, the company said it assumes no further tariff developments or increases.For the second quarter, the company reported a 15% increase in revenue to $506 million, surpassing an analyst estimate of $495.91 million, according to data from Fiscal AI. The company attributed the rise in revenue to strong demand for its EyeQ System-on-Chip, a custom hardware and software solution designed explicitly for Advanced Driver Assistance Systems (ADAS) and self-driving systems.Adjusted earnings per share came in at $0.13, compared to $0.09 in the corresponding quarter of 2024, and above an expected $0.11.A Stocktwits user opined that the stock is still a “bit expensive” and added that they would like a cheaper entry point.<stembedurl>https://stocktwits.com/eskitrades/message/622241885</stembedurl>&nbsp;&nbsp;Mobileye had $1.7 billion of cash and cash equivalents and zero debt as of June 28, 2025.MBLY stock is down by 20% this year and by about 29% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-registrations-slump-in-europe-yet-again-in-june/ch8ywW1R5HO">Tesla Registrations Slump In Europe Yet Again In June: Retail Sentiment Slips Amid 289% Jump In Chatter</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The Mobileye Global, Inc. logo appears on a smartphone screen in this illustration photo in Reno, United States, on December 23, 2024. (Photo by Jaque Silva/NurPhoto via Getty Images)

Mobileye CEO Sees Inflection In 2027 Growth Trajectory As Company Hikes Full-Year Revenue Outlook: Retail Thinks Stock Is Still A ‘Bit Expensive’

The company stated that the new guidance includes its estimates of production impacts related to current tariffs imposed on complete vehicles imported into the United States and tariffs on imported vehicle components used in U.S. vehicle production. 

Vertiv Holdings (VRT) surged more than 13% on Wednesday after the AI infrastructure firm raised its full-year guidance and signaled confidence in managing new tariffs under President Donald Trump’s trade policy.First-quarter (Q1) earnings came in at $0.64 per share, slightly above the $0.62 consensus estimate, according to Koyfin. Revenue for the quarter rose 24% year-over-year (YoY) to $2.04 billion, beating Wall Street’s $1.94 billion forecast. Organic net sales climbed 25%.The maker of power and cooling equipment for data centers said it now expects full-year 2025 revenue between $9.325 billion and $9.575 billion, up from its prior range of $9.125 billion to $9.275 billion.&nbsp;“We’re seeing accelerated scaling of AI deployments across the data center market,” said CEO Giordano Albertazzi. “Our partnership with Nvidia continues to place us at the heart of industrial-scale AI factory deployments.”He added that the updated forecast takes into account the anticipated impact of new U.S. tariffs, which have become a growing concern for manufacturers with global supply chains.“Although the tariff environment remains fluid, our goal is to significantly mitigate the effect of tariffs as we enter 2026,” he stated, adding that the company is working to mitigate the tariff impact through operational flexibility, a diversified manufacturing footprint, and commercial strategy shifts.The company said it continues to shift production to Mexico under the USMCA trade framework, and said only a single-digit percentage of its U.S. factory inputs currently come from China. Vertiv said it aims to have all U.S.-bound components manufactured in Mexico.Despite Wednesday’s rally,&nbsp;<a href="https://stocktwits.com/symbol/VRT">Vertiv’s stock</a> remains down more than 30% year-to-date, though it has held a 4% gain over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ge-vernova-cfo-sees-no-material-impact-from-trump-tariffs-on-outlook-q1-2025-earnings/chQmzXGRbgO">GE Vernova CFO Sees No ‘Material Impact’ From Trump Tariffs On Outlook – Stock Surges On Q1 2025 Earnings Beat</a>&nbsp;

In this photo illustration, the logo of Vertiv Holdings Co is displayed on a smartphone screen on April 20, 2025, in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

Vertiv Stock Surges On Q1 Beat, Improved 2025 Outlook — CEO Says Trump Tariff Impact Will Be Mitigated By 2026

The company now expects full-year 2025 revenue between $9.325 billion and $9.575 billion, up from its prior guidance of $9.125 billion to $9.275 billion. 

Oklo’s (OKLO) stock&nbsp;gained 0.7% in pre-market trade&nbsp;on Wednesday, reversing an earlier 3%&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/oklo-stock-slips-after-sam-altman-steps-down-as-chair/chQmNFmRbXx">drop</a> after the company announced that co-founder Sam Altman would step down as chairman.&nbsp;The news, while initially surprising to investors, may pave the way for a key energy deal with OpenAI, according to Citi analysts.In a research note cited by TheFly, Citi highlighted the leadership change as a potential catalyst for Oklo’s long-term prospects.&nbsp;While Altman’s “abrupt departure” caught investors off guard, Citi believes it could resolve any conflict of interest related to Oklo’s ongoing discussions with OpenAI about a potential energy supply agreement.&nbsp;The brokerage noted that given Altman’s dual roles at both Oklo and OpenAI, his exit could clear the path for a more strategic partnership in the future.Citi maintained its ‘Neutral’ rating on&nbsp;<a href="https://stocktwits.com/symbol/OKLO">Oklo’s stock</a>, with a $30 price target, noting that the company has been actively seeking new board members and considering the separation of the CEO and chairman roles.&nbsp;Analysts expect the initial market reaction to be negative, but they emphasized that a deal with OpenAI could alleviate these concerns, driving positive sentiment and potential stock upside.Meanwhile, H.C. Wainwright initiated coverage of Oklo with a ‘Buy’ rating and $55 price target, pointing to the company’s growing pipeline in advanced nuclear technology.&nbsp;It noted that Oklo has secured a 14 gigawatt (GW) pipeline, including a 12GW agreement with Switch, a data center developer, that extends through 2044.Oklo’s stock has gained 1.4% year-to-date and surged over 70% in the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/oklo-stock-slips-after-sam-altman-steps-down-as-chair/chQmNFmRbXx">Oklo Stock Slips After Sam Altman Steps Down As Chair, But Retail Sentiment Flips To 'Bullish'</a>

Sam Altman, former co-founder and CEO of OpenAI, speaks during a panel discussion titled "The Age of AI" at the Technical University of Berlin on February 07, 2025 in Berlin, Germany. (Photo by Sean Gallup/Getty Images)

Oklo-OpenAI Energy Deal More Likely After Sam Altman Exit, Says Citi

Citi noted that given Altman’s dual roles at both Oklo and OpenAI, his departure could pave the way for a more strategic partnership in the future.

Upstart Holdings Inc (UPST) shares surged about 26% in the after-market trade on Tuesday after the company posted a surprise profit and its fourth-quarter revenue beat Wall Street’s estimates.On an adjusted basis, the company posted earnings of $0.26 per share for the three months ended Dec. 31, compared with average analysts’ estimate of a loss of $0.15 per share.According to Koyfin data, the company reported quarterly revenue of $218.96 million, compared with the average analysts’ estimate of $181.92 million.Its net loss narrowed to $2.8 million, compared with $42.4 million in the same period last year.Upstart’s total loans jumped to 245,663 from 129,664 in the year-ago quarter, while its transaction volumes rose 66% to $2.1 billion.Its revenue from fees rose to $199.28 million from $152.86 million last year.The company expects to post $1 billion in revenue in 2025, which, if it meets its projections, will be a record annual revenue for the AI lending platform.Upstart also forecast a net interest income (NII) of about $80 million in 2025 and said it expects to at least break even this year. The company last posted a net profit in 2021.“In Q4 of 2024, our business grew dramatically across all product categories, delivered Adjusted EBITDA at levels not seen since the first quarter of 2022, and came within a whisker of returning to GAAP profitability,” CEO Dave Girouard said. &nbsp;Retail sentiment on Stocktwits moved higher in the ‘extremely bullish’ (96/100) territory, while retail chatter was ‘extremely high.’<figure class="image"><img style="aspect-ratio:803/184;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/UPST_Feb_12_d313e05882.JPG" alt="UPST’s Sentiment Meter and Message Volume as of 01:34 a.m. ET on Feb. 12, 2025 | Source: Stocktwits" width="803" height="184"><figcaption>UPST’s Sentiment Meter and Message Volume as of 01:34 a.m. ET on Feb. 12, 2025 | Source: Stocktwits</figcaption></figure>Users speculated if the stock could hit $350 soon, a level it last touched in 2021.<stembedurl>https://stocktwits.com/Koapark/message/603873161</stembedurl><stembedurl>https://stocktwits.com/drabon74/message/603874169</stembedurl>Over the past year, <a href="https://stocktwits.com/symbol/UPST">Upstart stock</a> has nearly doubled.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/energy-transfer-stock-falls-after-market-on-q4-revenue-miss-retail-shrugs-it-off/ch5aJ3ERub">Energy Transfer Stock Falls After-market On Q4 Revenue Miss: Retail Shrugs It Off</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Upstart Holdings logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Upstart Holdings Stock Soars Aftermarket After Surprise Q4 Profit: Retail’s Exuberant

On an adjusted basis, the company posted earnings of $0.26 per share for the three months ended Dec. 31, compared with average analysts’ estimate of a loss of $0.15 per share.

Shares of Cassava Sciences, Inc. (SAVA), a small-cap biotech firm, rose more than 5% on Tuesday after the company’s CEO, Rick Barry, provided an update on its Alzheimer’s drug trial via a regulatory 8-K filing.Barry announced that the ReTHINK Phase 3 clinical trial recently completed its final patient visit, marking a significant milestone in the development of Simufilam, a drug targeting a unique protein misfolding pathway associated with Alzheimer’s disease.Unlike traditional therapies that focus on amyloid plaques, Simufilam aims to correct the shape of the protein Filamin A, potentially addressing various Alzheimer’s disease processes.The ReTHINK trial enrolled 804 patients across 77 sites in the U.S., Puerto Rico, Canada, and Australia, with participants randomized between placebo and simufilam (100 mg twice daily). Approximately 70% of patients entered the study with mild Alzheimer’s, while the remaining 30% had moderate Alzheimer’s.Barry stated, “We expect to announce top-line results of the ReTHINK trial before year-end.” He mentioned that the proposed Statistical Analysis Plan was submitted to the FDA in July and is currently under review.Despite the positive news, retail sentiment on Stocktwits shifted from ‘bullish’ to ‘neutral’ after the update as of 1:00 pm ET. Cassava stock was the top trending ticker at 12:30 pm ET on Tuesday.<stembedurl>https://stocktwits.com/Tiffiny/message/588297923</stembedurl><stembedurl>https://stocktwits.com/Donniechen12345/message/588323050</stembedurl>The company had recently reached a $40 million settlement with the U.S. Securities and Exchange Commission (SEC) related to misleading claims about its Alzheimer’s drug trials, which had drawn considerable attention from retail investors.Following the CEO’s update, H.C. Wainwright upgraded Cassava Sciences to ‘Buy’ from ‘Neutral’, raising its price target to $116.The analyst believes the settlement has mitigated long-term challenges for the stock and anticipates a positive catalyst from the upcoming topline readout from the ReTHINK trial.Year-to-date, SAVA stock has climbed over 18%.For updates and corrections email <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>Read next: <a href="https://stocktwits.com/news-articles/markets/equity/ww-stock-rises-on-compounded-glp1-drug-offering/cJchFDeREX">WeightWatchers Stock Rallies After Adding Compounded Semaglutide To Offerings Amid GLP-1 Shortages: Retail Stays Cautious</a> &nbsp;

Cassava's simufilam aims to correct the shape of the protein Filamin A, potentially addressing various Alzheimer’s disease processes. 

Cassava Sciences Stock Jumps After CEO’s Update On Alzheimer’s Drug Trial: Retail Sentiment Wavers

The ReTHINK trial enrolled 804 patients across 77 sites in the U.S., Puerto Rico, Canada, and Australia, with participants randomized between placebo and simufilam (100 mg twice daily)

Shares of Cassava Sciences, Inc. (SAVA) fell more than 12% in pre-market trading on Friday, following the company’s announcement of a $40 million settlement with the U.S. Securities and Exchange Commission (SEC).The penalty, related to misleading claims made about its Alzheimer’s drug trials, drew significant attention from retail investors, making SAVA the top trending ticker on Stocktwits by 9 a.m. ET.The SEC charged Cassava and two former executives — founder and former CEO Remi Barbier and former Senior VP of Neuroscience Lindsay Burns — with making misleading statements in 2020 regarding the results of a clinical trial for their experimental Alzheimer's treatment, simufilam.The regulator alleged that the company claimed the drug "significantly improved patient cognition," while failing to disclose that full patient data showed "no measurable cognitive improvement" in episodic memory.Hoau-Yan Wang, a professor at the City University of New York Medical School who worked with Cassava to develop the drug, was also charged with manipulating trial data.Cassava agreed to the settlement without admitting or denying the charges."Cassava is pleased to put this matter behind us," CEO Richard Barry said in a statement. "We can now focus all of our attention on completion of the ongoing Phase 3 trials of simufilam.”<figure class="image"><a href="https://stocktwits.com/symbol/SAVA"><img style="aspect-ratio:1320/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/SAVA_stock_sentiment_and_message_volume_Sep_27_pre_market_d6f4e89110.png" alt="SAVA stock sentiment and message volume Sep 27 pre-market.png" width="1320" height="324"></a><figcaption>SAVA stock sentiment and message volume Sep 27 pre-market</figcaption></figure>Despite the stock’s sharp decline early on Friday, retail sentiment for SAVA remained ‘bullish’.Many investors on Stocktwits saw the settlement as a non-event, with some noting that the $40 million had already been set aside for the penalty.One user remarked, “We knew it was coming… This doesn’t take anyone by surprise.”<stembedurl>https://stocktwits.com/xNovah/message/587331181</stembedurl>Others were even more optimistic, focusing on the company’s Phase 3 trials, adding that with the SEC issue resolved, the path is clear for Cassava to move ahead with its clinical trials and potential FDA approval.<stembedurl>https://stocktwits.com/TagyouRit/message/587306764</stembedurl>Earlier this week, Cassava announced that a Data and Safety Monitoring Board completed a third interim safety review of simufilam, recommending that the ongoing Phase 3 studies continue without modifications.Chief Medical Officer Jim Kupiec stated that the company is on track to announce top-line data for the 12-month Phase 3 study by the end of 2024.Despite recent setbacks, SAVA stock is still up more than 40% year-to-date. Retail investors appear to be holding out hope for a potential breakthrough as the company moves closer to critical trial results later this year.Read next: <a href="https://stocktwits.com/news/markets/equity/djt-stock-falls-after-co-founder-litinsky-slashes-stake/c7CUFDdR3G">Trump Media Stock Faces Pressure As Co-Founder Nearly Exits Stake: Retail Still Bullish</a> &nbsp;

The SEC said the company made misleading statements in 2020 regarding the results of a clinical trial for their experimental Alzheimer's treatment, simufilam. 

Cassava Sciences Stock Slides After $40M SEC Settlement Over Misleading Alzheimer’s Trial Claims, Captures Retail Spotlight

Many investors on Stocktwits saw the settlement as a non-event, with some noting that the penalty had already been priced in. 

Africa-based e-commerce platform Jumia Technologies’ shares dove nearly 48% on Tuesday after the firm announced its intention to raise funds by issuing over 20.22 million American Depositary Shares (ADS).The firm intends to use the proceeds to help support customer acquisition, expansion of supplier base, scaling its logistics network and improving marketing and vendor technology. It also cited general corporate purposes.However, retail investors are shrugging-off the fundraise news while concentrating on its improving operating metrics.Jumia Technologies’ Q2 revenue declined 17% year-over-year (YoY) to $36.50 million but operating loss narrowed to $20.20 million compared to $22.10 million in the same period a year ago.The firm said its quarterly cash burn declined 55% driven by effective cost management and reduction in finance costs. Its finance costs for the second quarter were mainly influenced by losses recognized on the sale of financial assets. Jumia also reported a 35% jump in its gross merchandise value (GMV) at $170.10 million (constant currency basis).Notably, 67% of the company’s liquidity position was held in U.S. dollars as of the second quarter of 2024. Jumia said it continues to refine its cash repatriation strategy.Following the announcement, retail sentiment shifted into the ‘bullish’ territory (76/100) from the bearish zone, while message volumes hit a one-year high.<figure class="image"><a href="https://stocktwits.com/symbol/JMIA"><img style="aspect-ratio:1572/450;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_08_06_at_12_34_50_PM_47e543ee3d.png" alt="Jumia Technologies’ sentiment meter as of 12:09 p.m. EST on August 06, 2024" width="1572" height="450"></a><figcaption>Jumia Technologies’ sentiment meter as of 12:09 p.m. EST on August 06, 2024</figcaption></figure>The firm is also attracting more quality customers, showing a 262 basis points YoY improvement in repurchase rates during the first quarter of 2024.According to the company’s analysis, 36% of new customers who placed an order for a product or a service on its platform in Q1 completed a second purchase within 90 days. “This represents an improvement compared to 33% of new customers from the first quarter of 2023, who reordered within 90 days,” it said.Jumia now projects an increase in both orders and GMV in 2024, excluding the potential impact of foreign exchange. Stocktwits bulls are betting on the long-term prospects of the firm while expecting continued improvements in its underlying business trends. &nbsp;<figure class="image"><a href="https://stocktwits.com/glasshouse56/message/581969568"><img style="aspect-ratio:1550/310;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_08_06_at_12_38_52_PM_a7683afc99.png" alt="Stocktwits user glasshouse56's post on Jumia Technologies" width="1550" height="310"></a><figcaption>Stocktwits user glasshouse56's post on Jumia Technologies</figcaption></figure>

Jumia Technologies will be issuing over 20.22 million American Depositary Shares turning Wall Street against it.

Jumia Technologies Falls 48% After Fundraise Disclosure But Retail Focuses On Improving Operating Metrics

Jumia Technologies will be issuing over 20.22 million American Depositary Shares turning Wall Street against it. But retail investors believe the firm’s improving metrics and newfound liquidity lays the foundation for better long-term prospects.

ULTY
YieldMax Ultra Option Income Strategy ETF

Feed

News

Sentiment

Fundamentals

Info

Latest ULTY News

ULTY YieldMax Ultra Option Income Strategy ETF